Sitagliptin and Angioedema
Authors: Robin Arcani, Sonia Martinez, Stéphane Gayet
Journal: Annals of Internal Medicine (2017)

Letters18 July 2017Sitagliptin and AngioedemaRobin Arcani, MD, Sonia Martinez, MD, and Stéphane Gayet, MDRobin Arcani, MDFrom Centre Hospitalier Universitaire La Timone, Marseille, and Centre Hospitalier de la Ciotat, La Ciotat, France., Sonia Martinez, MDFrom Centre Hospitalier Universitaire La Timone, Marseille, and Centre Hospitalier de la Ciotat, La Ciotat, France., and Stéphane Gayet, MDFrom Centre Hospitalier Universitaire La Timone, Marseille, and Centre Hospitalier de la Ciotat, La Ciotat, France.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0649 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Some patients develop angioedema when they receive an angiotensin-converting enzyme inhibitor (ACEI) alone; others do so only when they receive an ACEI plus a dipeptidyl peptidase-4 (DPP-4) inhibitor (1). However, angioedema rarely develops in patients who receive a DPP-4 inhibitor without an ACEI.Objective: To describe a patient who develops severe angioedema while receiving a DPP-4 inhibitor without an ACEI.Case Report: A 59-year-old man presented to the emergency department for a swollen tongue. The patient was a current cigarette smoker and had a 3-year history of type 2 diabetes. His diabetes had been treated with metformin until 3 ...References1. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516-23. [PMID: 19581505] doi:10.1161/HYPERTENSIONAHA.109.134197 CrossrefMedlineGoogle Scholar2. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-7. [PMID: 10963200] CrossrefMedlineGoogle Scholar3. Charignon D, Ghannam A, Defendi F, Ponard D, Monnier N, L pez Trascasa M, et al. Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype. Allergy. 2014;69:1659-65. [PMID: 25134986] doi:10.1111/all.12515 CrossrefMedlineGoogle Scholar4. Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin [Letter]. Int J Cardiol. 2013;168:e106. [PMID: 23972359] doi:10.1016/j.ijcard.2013.07.257 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Centre Hospitalier Universitaire La Timone, Marseille, and Centre Hospitalier de la Ciotat, La Ciotat, France.Acknowledgment: The authors thank C. Drouet for exploring the catabolism of the bradykinin.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0649.This article was published at Annals.org on 30 May 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor AngioedemaAngioedema following initiation of glecaprevir/pibrentasvir while on sitagliptinDPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in miceTwenty years of adverse drug reactions: a look back – part 2Sitagliptin 18 July 2017Volume 167, Issue 2Page: 142-143KeywordsAngiotensin converting enzyme inhibitorCoagulation factorsDisclosureDyspneaEdemaEmergency departmentEpinephrineHereditary angioedemaMast cellsTongue ePublished: 30 May 2017 Issue Published: 18 July 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...